Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
about
Neuroinflammatory responses in diabetic retinopathyTargeting inflammation in diabetes: Newer therapeutic optionsNovel pharmacotherapies in diabetic retinopathyTherapeutic interventions against inflammatory and angiogenic mediators in proliferative diabetic retinopathyMatrix metalloproteinase-9 contributes to choroidal neovascularization.Current and future pharmacological intervention for diabetic retinopathy.Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras.Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction.High intravitreal TGF-β1 and MMP-9 levels in eyes with retinal vein occlusionRelationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathyThe α7-nicotinic acetylcholine receptor and MMP-2/-9 pathway mediate the proangiogenic effect of nicotine in human retinal endothelial cells.Matrix Metalloproteinase-1 and Matrix Metalloproteinase-9 in the Aqueous Humor of Diabetic Macular Edema Patients.What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus?Genetic variations and plasma levels of gelatinase A (matrix metalloproteinase-2) and gelatinase B (matrix metalloproteinase-9) in proliferative diabetic retinopathyThe eye and the heart.Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metalloproteinase-2.Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9.VEGF secreted by hypoxic Müller cells induces MMP-2 expression and activity in endothelial cells to promote retinal neovascularization in proliferative diabetic retinopathy.Differential systemic gene expression profile in patients with diabetic macular edema: responders versus nonresponders to standard treatment.New insights into hyperglycemia-induced molecular changes in microvascular cells.The role of glia in retinal vascular disease.Doxycycline blocks gastric ulcer by regulating matrix metalloproteinase-2 activity and oxidative stress.The ERK1/2 Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and Biomarkers of Inflammation in the Retina.Diabetic retinopathy and inflammation: novel therapeutic targets.Role of inflammation in the pathogenesis of diabetic retinopathy.Intraocular matrix metalloproteinase 2 and 9 in patients with diabetes mellitus with and without diabetic retinopathy.Metalloproteinases as mediators of inflammation and the eyes: molecular genetic underpinnings governing ocular pathophysiologyEfficacy of Prinomastat) (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization.Increased intravitreal angiopoietin-2 levels associated with rhegmatogenous retinal detachment.Role of Inflammation in Diabetic Retinopathy.Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy.Upregulation of collagenase-1 and -3 in indomethacin-induced gastric ulcer in diabetic rats: role of melatonin.
P2860
Q26798351-40C493EE-E7E3-44A3-9A34-100375BB3D83Q26852726-67384D3C-47E7-4E82-88FB-41BD316C483DQ27002622-EA45A044-3FDC-427D-A0A8-E93298453D3EQ27021701-BCF9FF1D-A861-4816-9386-67D6E13C29FAQ30860298-DA5FDE36-4561-4EE8-A843-62AF9322C12AQ33216425-F5C938BE-F7D4-4743-A843-0F33E5AAD7C1Q34022639-E20E32E8-C352-4AD2-9E10-02CEBE26AAD9Q34077433-D315E227-60E5-4487-BC78-7E49711C642EQ34200359-B7985A79-1FC6-4F23-9577-75FBA8E461C9Q35083186-21C83B56-A572-48B4-ABE0-810A221BE85FQ35221001-FA31A7C1-70C6-48B0-95E5-3405EABEFABCQ36088748-0575967C-910D-44F3-91B6-9F7DBA57F580Q36364062-FA0174F2-0FA6-4E45-88C6-B4C41F0551C6Q36717869-9121CC4C-6032-41DF-8797-7C6A6F7063F5Q36806038-EDC583EC-4893-4DB7-A065-CC2F074748C5Q37195371-A1E1F047-B6C7-4414-B62F-12CE563A6C03Q37242419-FA106356-32D8-4B67-85F0-560C7512756FQ37251091-3A5578C8-4C81-4359-94C8-08E6B27CC341Q37638770-CAB04918-11F8-4D1B-A77A-47AA3644ED34Q37665090-8EC82D41-4AE2-4421-9DDB-78AE123EA1C2Q38004034-E440FEEE-3263-4F2F-B4CD-A1C629F265E7Q38256173-776B21C2-770C-4312-8299-BF6B5DF53445Q40509325-4384F4E2-C636-4259-9991-5A8736A03133Q41012046-20EF4FC2-CBB5-4343-9467-84E5AFE2D78DQ41012127-8448AAA9-980C-4AF3-9406-44D4B4C6D7C6Q41287573-7CA36B1C-8DF8-4182-9274-174F30390011Q41374334-0495B6BE-1833-428C-B9B8-0411A6A9B746Q44108830-AA71FBF0-2FC2-416D-90D9-DB0B8986DE9CQ45905920-9DBF74EC-B367-4265-9141-5C850C23172AQ52642996-594F2EA5-C1C6-4FAE-8CF1-7D201A787C44Q53111788-98A5130C-5E7B-47FC-9531-4E7C4D22D455Q54611080-06D8A5AC-C0E8-4B9D-BB15-5072BA57B456
P2860
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
@ast
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
@en
type
label
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
@ast
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
@en
prefLabel
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
@ast
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
@en
P2093
P1433
P1476
Matrix metalloproteinases in human diabetic and nondiabetic vitreous.
@en
P2093
P356
10.1097/00006982-200102000-00005
P577
2001-01-01T00:00:00Z